ArticleMolecules (Basel, Switzerland)2026
Impact of Cannabidiol and Its Synthetic Derivative on Fentanyl Consumption and Fentanyl-Induced Neurometabolic Alterations in Mice.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOpioid use disorder (OUD) remains a critical global health challenge, with highly potent synthetic opioids like fentanyl contributing to overdose deaths. The available treatments have limitations. The endocannabinoid system has emerged steadily as a therapeutic target for the opioid crisis due to its modulatory effects on opioid reward and withdrawal and its involvement in regulating inflammation. These studies investigate the potential of cannabidiol (CBD) and its synthetic derivative (L-1β IN-1) in mitigating fentanyl effects.
methodsC57BL/6 male mice were used in several behavioral assays: two-bottle choice (TBC) to measure fentanyl reward/seeking behaviors, hot plate to assess antinociception, and marble burying to evaluate compulsive/adverse effects. Additionally, a neurometabolic study was conducted to evaluate the impact of chronic high doses of fentanyl alone and in combination with CBD or L-1β-IN-1 on brain metabolic signatures.
resultsThe mice consistently preferred to drink fentanyl, and i.p. injections of 10 mg/kg CBD or 5-25 mg/kg of L-1β-IN-1 decreased the fentanyl preference scores to values below 0.5. The antinociceptive effects of pretreatment groups showed a trend of enhanced analgesic effects in the hot plate assay. However, they showed no significant changes in the marble-burying assay, suggesting that pretreatment with these compounds lacks acute stereotypic effects. The Fentanyl metabolomics revealed robust metabolic activation with fentanyl alone, while CBD or L-1β-IN-1 showed different profiles in modulating these fentanyl-induced metabolic signatures.
conclusionsThese studies provide evidence about the in vivo behavioral and neurometabolic profiles of fentanyl after pretreatment with CBD and synthetic CBD, presenting them as possible pharmacological tools for OUD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.